Tempus AI, Inc. (NASDAQ:TEM) Stock Has Consensus Target Price of $71.05 According to Brokerages

Tempus AI, Inc. (NASDAQ:TEM) has been given an average recommendation of “Hold” by the twenty-two analysts that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $72.37.

Several analysts have commented on TEM shares. HC Wainwright increased their target price on Tempus AI from $56.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, September 11th. Wall Street Zen upgraded Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Stifel Nicolaus lowered their price target on Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a report on Monday, August 3rd. Guggenheim increased their price objective on Tempus AI from $65.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Finally, Roth Capital initiated coverage on Tempus AI in a research report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price objective on the stock.

Insiders Place Their Bets

In other news, CEO Eric P. Lefkofsky sold 250,000 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $42.06, for a total transaction of $10,515,000.00. Following the sale, the chief executive officer owned 200,000 shares of the company’s stock, valued at $8,412,000. This trade represents a 55.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Polovin sold 22,148 shares of Tempus AI stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the completion of the sale, the executive vice president owned 146,067 shares of the company’s stock, valued at $7,246,383.87. This represents a 13.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 1,280,965 shares of company stock worth $80,397,564 in the last 90 days. Corporate insiders own 24.26% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sumitomo Mitsui Trust Group Inc. raised its stake in Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after buying an additional 821,490 shares during the last quarter. Amova Asset Management Americas Inc. lifted its holdings in shares of Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after buying an additional 821,490 shares during the period. Clear Street Group Inc. boosted its stake in shares of Tempus AI by 1.0% in the 4th quarter. Clear Street Group Inc. now owns 723,365 shares of the company’s stock worth $42,715,000 after buying an additional 6,959 shares during the last quarter. Eagle Health Investments LP purchased a new position in shares of Tempus AI in the 1st quarter worth $11,588,000. Finally, Swiss National Bank boosted its stake in shares of Tempus AI by 0.3% in the 1st quarter. Swiss National Bank now owns 183,500 shares of the company’s stock worth $8,298,000 after buying an additional 600 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI Trading Up 0.1%

NASDAQ:TEM opened at $68.32 on Monday. The company’s 50 day moving average price is $67.31 and its 200-day moving average price is $56.23. Tempus AI has a 52 week low of $40.77 and a 52 week high of $97.25. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The stock has a market cap of $12.33 billion, a price-to-earnings ratio of -47.44 and a beta of 3.54.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. During the same quarter last year, the firm earned ($0.22) earnings per share. The firm’s quarterly revenue was up 21.6% compared to the same quarter last year. On average, equities research analysts forecast that Tempus AI will post -1.38 earnings per share for the current fiscal year.

Tempus AI Company Profile

Tempus AI, Inc is a technology company focused on applying artificial intelligence and data analytics to precision medicine. The company develops tools intended to help physicians make more informed treatment decisions by combining clinical information, molecular data and other health-related datasets.

Tempus provides genomic testing and diagnostic services, including sequencing and other molecular tests used primarily in oncology. Its platform also offers data and software solutions designed to support clinical research, pharmaceutical development, patient identification for clinical trials and the development of personalized treatment strategies.

Founded in 2015, Tempus is headquartered in Chicago and primarily serves healthcare providers, researchers and life sciences companies.